Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.
Stefanie HammerAndreas SchlickerSabine Zitzmann-KolbeSimon BaumgartUrs B HagemannArne ScholzBernard HaendlerPascale LejeuneJenny KarlssonChristine EllingsenHartwig HennekesCarsten H NielsenMark U JuulDominik MumbergChristoph A SchatzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
These results provide a strong rationale to investigate PSMA-TTC in combination with AR inhibitors in patients with prostate cancer.